CoChat

Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects

Open access
Mehta, Amit R., Armstrong, Andrew J. · 2016 · Therapeutic Advances in Urology

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Treatment options have significantly expanded in recent years for men with metastatic castration-resistant prostate cancer (mCRPC), with the routine use of immunotherapy (sipuleucel-T) and novel hormonal agents such as enzalutamide and abiraterone acetate prior to taxane-based chemotherapy or radium-223 radiotherapy. A number of immune checkpoints limit the immune response of the host to metastatic tumor progression in prostate cancer, one of which is an immunosuppressive and pro-angiogenic cell called the myeloid-derived suppressor cell (MDSC). Tasquinimod is a small molecular oral inhibitor of S100A9, a key cell surface regulator of MDSC function, and has shown anti-angiogenic, antitumor and immune-modulatory properties in preclinical models of prostate cancer and other solid tumors. A large randomized phase II trial of tasquinimod in men with chemotherapy-naïve mCRPC demonstrated a significant prolongation in radiographic and symptomatic progression-free survival compared with placebo, which was also associated with improvements in overall survival. Tasquinimod was studied in a global phase III randomized trial in men with bone mCRPC and, while it significantly improved radiographic progression-free survival, this did not result in an overall survival benefit. However, tasquinimod is under evaluation as well as a combination therapy with other systemic agents in prostate cancer and as a single agent in other solid tumors. This review encompasses the preclinical and clinical development of tasquinimod as a therapy for men with prostate cancer.

Overview

Integrity signals

Registry

Crossref · 10.1177/1756287215603558

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 4

  1. Becker Y., 2006, Anticancer Res, 26, 1113
  2. Ichikawa T., 1992, Cancer Res, 52, 3022
  3. Isaacs J., 2012, Cancer Res, 73, 1
  4. Thoreson G., 2014, Can J Urol, 21, 98

Cited by

See all 42

Metadata

Authors
Mehta, A. R., & Armstrong, A. J.
Affiliations
  • Duke Cancer Institute (US)
  • Duke University (US)
Corresponding author
Armstrong, Andrew J.
Venue
Therapeutic Advances in Urology
Published
2015-09-16
Volume
8
Issue
1
Pages
9-18
ISSN
  • 1756-2872 (ISSN-L)
  • 1756-2880
OpenAlex
W2219233634
Cited by
41
References
31
Citations by year
2026: 6 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 2 · 2019: 1 · 2017: 2 · 2016: 8
FWCI
2.64
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Urology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
tasquinimod, castration-resistant prostate cancer, metastatic prostate cancer, myeloid-derived suppressor cells, immune checkpoint, anti-angiogenic therapy, progression-free survival, overall survival, combination therapy, bone metastasis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects. https://app.cochat.ai/papers/10.1177/1756287215603558
The paper
Mehta, A. R., & Armstrong, A. J. (2016). Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects. Therapeutic Advances in Urology. https://doi.org/10.1177/1756287215603558

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.